

Amendment to the Claims

Please amend claims 3-7, 10-14, and 17-21 as follows:

1. (Original) A method of treating an individual who has been identified as being infected with a Flavivirus, Pestivirus, picornovirus or coronavirus, comprising administering to said individual a therapeutically effective amount of one or more glucocorticoid receptor antagonist compounds, wherein said compound has steroidal structure.
2. (Original) The method of claim 1 wherein said compound has a steroidal structure free of a hydroxylated group at position 11 β .
3. (Currently amended) The method ~~of any one of~~ claims 1-2 wherein the individual who has been identified as being infected with a HCV, GB virus B, JEV, WNV, CSFV, BDV, BVDV, poliovirus, FMDV, or EMCV
4. (Currently amended) The method ~~of any one of~~ claims 1-3 wherein a glucocorticoid receptor antagonist compound selected from the group consisting of: mifepristone, Compound D1, Compound D2, Compound D3, Compound D4, Compound D5, Compound D6, Compound D7, Compound D8, pharmaceutically acceptable salts thereof and combinations thereof is administered to said individual.
5. (Currently amended) The method ~~of any one of~~ claims 1-4 wherein mifepristone is administered to said individual.
6. (Currently amended) The method ~~of any one of~~ claims 1-5 wherein one or more antiviral compounds selected from the group consisting of: acyclovir, ganciclovir, foscarnet, lamivudine, ribavirin, interferon alpha-2a, interferon alpha-2b, peginterferon alfa-2a, and peginterferon alfa-2b thereof is administered to said individual.

7. (Currently amended) The method ~~of any one of~~ claims 1-6 wherein the individual who has been identified as being infected with a HCV.
8. (Original) A method of preventing infection by a Flavivirus, Pestivirus, picornovirus or coronavirus in an individual suspected of having been exposed to such a virus comprising administering to said individual a prophylactically effective amount of one or more glucocorticoid receptor antagonist compounds, wherein said compound has steroidal structure
9. (Original) The method of claim 8 wherein said compound has a steroidal structure free of a hydroxylated group at position 11 β
10. (Currently amended) The method ~~of any one of~~ claims 8-9 wherein the virus is HCV, GB virus B, JEV, WNV, CSFV, BDV, BVDV, poliovirus, FMDV, or EMCV.
11. (Currently amended) The method ~~of any one of~~ claims 8-10 wherein a glucocorticoid receptor antagonist compound selected from the group consisting of: mifepristone, Compound D1, Compound D2, Compound D3, Compound D4, Compound D5, Compound D6, Compound D7, Compound D, pharmaceutically acceptable salts thereof and combinations thereof is administered to said individual.
12. (Currently amended) The method ~~of any one of~~ claims 8-11 wherein mifepristone is administered to said individual.
13. (Currently amended) The method ~~of any one of~~ claims 8-12 wherein one or more antiviral compounds selected from the group consisting of: acyclovir, ganciclovir, foscarnet, lamivudine, ribavirin, interferon alpha-2a, interferon alpha-2b, peginterferon alfa-2a, and peginterferon alfa-2b thereof is administered to said individual.
14. (Currently amended) The method ~~of any one of~~ claims 8-13 wherein the virus is HCV.

15. (Original) A pharmaceutical composition comprising one or more glucocorticoid receptor antagonist compounds having a steroidal structure in a therapeutically effective amount to treat or prevent Flavivirus, Pestivirus, picornavirus or coronavirus infection.
16. (Original) The pharmaceutical composition of claim 15 wherein said compound having a steroidal structure is free of a hydroxylated group at position 11 β
17. (Currently amended) The pharmaceutical composition ~~of any one of~~ claims 15-17 in a therapeutically effective amount to treat or prevent HCV, GB virus B, JEV, WNV, CSFV, BDV, BVDV, poliovirus, FMDV, or EMCV infection.
18. (Currently amended) The pharmaceutical composition ~~of any one of~~ claims 15-17 comprising a glucocorticoid receptor antagonist compound selected from the group consisting of: mifepristone, Compound D1, Compound D2, Compound D3, Compound D4, Compound D5, Compound D6, Compound D7, Compound D8, pharmaceutically acceptable salts thereof and combinations thereof.
19. (Currently amended) The pharmaceutical composition ~~of any one of~~ claims 15-18 comprising mifepristone.
20. (Currently amended) The pharmaceutical composition ~~of any one of~~ claims 15-19 further comprising one or more antiviral compounds selected from the group consisting of: acyclovir, ganciclovir, foscarnet, lamivudine, ribavirin, interferon alpha-2a, interferon alpha-2b, peginterferon alfa-2a, and peginterferon alfa-2b.
21. (Currently amended) The pharmaceutical composition ~~of any one of~~ claims 15-20 in a therapeutically effective amount to treat or prevent HCV infection.